Brief: Assembly Biosciences Doses First Participant In Phase 1A/B Clinical Trial Of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366
10/06/2024 13:07
June 10 (Reuters) - Assembly Biosciences Inc ASMB.O :
* ASSEMBLY BIOSCIENCES DOSES FIRST PARTICIPANT IN PHASE 1A/B
CLINICAL TRIAL OF HERPES SIMPLEX VIRUS HELICASE-PRIMASE
INHIBITOR CANDIDATE ABI-5366
* ASSEMBLY BIOSCIENCES INC: INTERIM DATA FROM PHASE 1A STUDY
EXPECTED IN Q3 2024
Source text for Eikon: ID:nGNXc5KGxq
Further company coverage: ASMB.O
((Reuters.Briefs@thomsonreuters.com;))